(Q57272462)

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Advances in chromatin remodeling and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Anti-tumor mechanisms of valproate: a novel role for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Histone deacetylase inhibitors in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Preclinical antitumor activity of CI-994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Chronic oral administration of CI-994: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Antitumor activity of tributyrin in murine melanoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

The fundamental role of epigenetics in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Modulation of radiation response by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in v

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.5.659